You are here

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Dallas, Texas, 75204 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Postmenopausal female patient with histologically or cytologically confirmed breast
cancer having progressed on Tamoxifen.

- Advanced disease: patients with advanced breast carcinoma with disease progression who
had progressed/relapsed following > 8 weeks of treatment with Tamoxifen for advanced
disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending
on receptor status; or progressed within 12 months from completion of adjuvant
treatment with Tamoxifen.

- at least one measurable lesion

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- More than one previous chemotherapy and/or more than one hormonotherapy for advanced
disease.

- Previous hormonotherapy for advanced disease other than Tamoxifen.

- Myocardial infarction within previous 6 mo

NCT00038103
Pfizer
Completed
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neoplasms, Breast Neoplasms
NCT03343054
All Genders
20+
Years
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
NCT03284723
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now